| Titolo |
Pubblicato in |
Anno |
| PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey |
TUMORI |
2024 |
| Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis |
BMC CANCER |
2024 |
| The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients |
PATHOLOGY RESEARCH AND PRACTICE |
2024 |
| Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis |
BMC CANCER |
2024 |
| Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) |
NPJ BREAST CANCER |
2024 |
| Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach |
CANCER IMMUNOLOGY, IMMUNOTHERAPY |
2023 |
| Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2023 |
| PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey |
TUMORI |
2023 |
| Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study |
LIFE |
2023 |
| The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature |
FRONTIERS IN ONCOLOGY |
2022 |
| Renal function outcomes in metastatic non-small-cell lung carcinoma patients treated with chemotherapy or immune checkpoint inhibitors: an unexpected scenario |
VACCINES |
2022 |
| Dental Implant Failure Risk in Post Oncological Patients, a Retrospective Study and Sapienza Head and Neck Unit Decisional Protocol- 7 Years of Follow-Up |
DIAGNOSTICS |
2022 |
| Dental Implant Failure Risk in Post Oncological Patients, a Retrospective Study and Sapienza Head and Neck Unit Decisional Protocol- 7 Years of Follow-Up |
DIAGNOSTICS |
2022 |
| Genomic and immune approach in platinum refractory HPV-negative head and neck squamous cell carcinoma patients treated with Immunotherapy: a novel combined profile |
BIOMEDICINES |
2022 |
| The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy |
FRONTIERS IN IMMUNOLOGY |
2022 |
| Oral immune-related adverse events associated with PD-1 inhibitor treatment: a case series |
APPLIED SCIENCES |
2022 |
| DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients |
ANNALS OF ONCOLOGY |
2022 |
| Ideal regimen for induction chemotherapy in nasopharyngeal cancer: Still a hot issue? |
RADIOTHERAPY AND ONCOLOGY |
2022 |
| The role of opioids in cancer response to immunotherapy |
JOURNAL OF TRANSLATIONAL MEDICINE |
2021 |
| Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
JOURNAL OF TRANSLATIONAL MEDICINE |
2021 |
